CRISPR Therapeutics Aktie
41,61
EUR
-1,50
EUR
-3,47
%
48,60
USD
+0,19
USD
+0,39
%
Werbung
CRISPR Therapeutics Aktie Analyse
| 26.07.19 | CRISPR Therapeutics Buy | Canaccord Adams | |
| 30.11.18 | CRISPR Therapeutics Buy | Needham & Company, LLC | |
| 15.05.18 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
| 28.03.17 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
| 14.11.16 | CRISPR Therapeutics overweight | Barclays Capital |
Werbung
Werbung